TY - JOUR
T1 - Insulin-sensitizing agents: Use in pregnancy and as therapy in polycystic ovary syndrome
AU - Requena, A.
AU - Salvador, C.
AU - Tur, R.
AU - Callejo, J.
AU - Espinós, J. J.
AU - Fábregues, F.
AU - Herrero, J.
AU - Checa Vizcaino, Miguel Angel
PY - 2005/7/1
Y1 - 2005/7/1
N2 - Treatment with insulin-sensitizing agents is a relatively recent therapeutic strategy in women with polycystic ovary syndrome (PCOS) and insulin resistance. The key areas addressed in this review include PCOS and the development of type 2 diabetes mellitus and gestational diabetes, as well as the use of insulin-sensitizing agents, particularly metformin, in the management of infertility in obese and non-obese PCOS women. Treatment with metformin in PCOS women undergoing IVF and the use of metformin during gestation will be discussed. The challenge for the health care professional should be the appropriate utilization of pharmacotherapies to improve insulin sensitivity and lower circulating insulin levels resulting in beneficial changes in PCOS phenotype. Further research into the potential role of other insulin-sensitizing agents, such as pioglitazone and rosiglitazone, in the treatment of infertile women with PCOS is needed. © The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
AB - Treatment with insulin-sensitizing agents is a relatively recent therapeutic strategy in women with polycystic ovary syndrome (PCOS) and insulin resistance. The key areas addressed in this review include PCOS and the development of type 2 diabetes mellitus and gestational diabetes, as well as the use of insulin-sensitizing agents, particularly metformin, in the management of infertility in obese and non-obese PCOS women. Treatment with metformin in PCOS women undergoing IVF and the use of metformin during gestation will be discussed. The challenge for the health care professional should be the appropriate utilization of pharmacotherapies to improve insulin sensitivity and lower circulating insulin levels resulting in beneficial changes in PCOS phenotype. Further research into the potential role of other insulin-sensitizing agents, such as pioglitazone and rosiglitazone, in the treatment of infertile women with PCOS is needed. © The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
KW - Diabetes
KW - Insulin-sensitizing agents
KW - Metformin
KW - Obesity
KW - Polycystic ovary syndrome
U2 - 10.1093/humupd/dmi015
DO - 10.1093/humupd/dmi015
M3 - Review article
SN - 1355-4786
VL - 11
SP - 375
EP - 390
JO - Human Reproduction Update
JF - Human Reproduction Update
IS - 4
ER -
